Stockscreener 앱 받기
0.9096
3.36%
0.0296
시간 외 거래:
.94
0.0304
+3.34%
전일 마감가:
$0.88
열려 있는:
$0.87
하루 거래량:
727.96K
Relative Volume:
1.55
시가총액:
$61.62M
수익:
$208.60K
순이익/손실:
$-58.59M
주가수익비율:
-0.9926
EPS:
-0.9164
순현금흐름:
$-47.11M
1주 성능:
-7.27%
1개월 성능:
+4.22%
6개월 성능:
-32.12%
1년 성능:
-28.94%
1일 변동 폭
$0.81
$0.9396
1주일 범위
$0.81
$1.04
52주 변동 폭
$0.7113
$1.94
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.9096 | 59.62M | 208.60K | -58.59M | -47.11M | -0.9164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | 재개 | H.C. Wainwright | Buy |
| 2025-05-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-02-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-06 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | 개시 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-04-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-05 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-06-05 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-01-29 | 개시 | Robert W. Baird | Outperform |
| 2018-12-10 | 개시 | Credit Suisse | Outperform |
| 2018-07-13 | 개시 | BMO Capital Markets | Outperform |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-28 | 개시 | SunTrust | Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Inflarx N V 주식(IFRX)의 최신 뉴스
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
IFRX: Izicopan's promising Phase 2a data drives strategic focus and extends cash runway to mid-2027 - TradingView
InflaRx (NASDAQ:IFRX) Issues Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027 - TipRanks
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - The Manila Times
InflaRx (IFRX) narrows 2025 loss, shifts focus to izicopan growth - Stock Titan
IFRX: Izicopan advances as the lead asset with strong Phase 2a data, cost cuts, and extended cash runway - TradingView
InflaRx to present Phase 3 pyoderma gangrenosum data at AAD By Investing.com - Investing.com South Africa
InflaRx FY 2025 earnings preview - MSN
Aug Opening: Is InflaRx NV forming bullish engulfing patterns2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
Aug Levels: Can InflaRx NV outperform under higher oil prices2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
InflaRx (IFRX) director Mark Kubler reports 960,015 shares and multiple options - Stock Titan
InflaRx (IFRX) director lists options and 10,000 Ordinary Shares - Stock Titan
InflaRx (IFRX) director details vested and future stock options - Stock Titan
InflaRx (IFRX) CSO discloses 1.76M shares and multiple option grants - Stock Titan
InflaRx (IFRX) officer discloses vested and performance stock options - Stock Titan
InflaRx (IFRX) director discloses sizeable share and option stakes - Stock Titan
InflaRx (IFRX) CEO reports 1,068,908 shares plus option grants - Stock Titan
InflaRx (IFRX) CFO details extensive stock option and share holdings - Stock Titan
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting - The Manila Times
InflaRx N.V. to Present Phase 3 Study Data on Vilobelimab for Pyoderma Gangrenosum at AAD 2026 Annual Meeting - Quiver Quantitative
Vilobelimab Phase 3 data earns late-breaker slot at AAD 2026 meeting - Stock Titan
InflaRx NV expected to post a loss of 15 cents a shareEarnings Preview - TradingView
InflaRx (IFRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
InflaRx receives Nasdaq notification - MSN
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Sahm
InflaRx Receives Nasdaq Deficiency Notice Over Minimum Bid Price - National Today
InflaRx (IFRX) hit with Nasdaq minimum $1 bid-price warning and cure window - Stock Titan
InflaRx receives Nasdaq notice over minimum bid price rule - Investing.com
InflaRx to Report Full Year 2025 Results on March 19, 2026 - Bitget
InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat
IFRX: Izicopan advances as a lead asset with strong HS data, new indications, and global expansion plans - TradingView
Breakout Move: Can InflaRx N.V. stock maintain growth trajectoryWeekly Trend Report & Growth Focused Stock Reports - Naître et grandir
Market Leaders: Is InflaRx NV a top pick in the sectorGap Down & Weekly Stock Performance Updates - baoquankhu1.vn
What RSI levels show for InflaRx N.V. (IF0) stock2025 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - Naître et grandir
Shorts Report: Can APCXW maintain sales growthTrade Volume Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Analysts Set InflaRx N.V. (NASDAQ:IFRX) Target Price at $7.50 - Defense World
IFRX Earnings History & Surprises | EPS & Revenue Results | INFLARX NV (NASDAQ:IFRX) - ChartMill
Aug Macro: Whats the analyst consensus on InflaRx NV2025 Market Sentiment & Community Consensus Stock Picks - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference - Bitget
InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference - MarketBeat
InflaRx N.V. (IFRX) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
IFRX Should I Buy - Intellectia AI
IFRX PE Ratio & Valuation, Is IFRX Overvalued - Intellectia AI
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit - MarketBeat
IFRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Will InflaRx N.V. stock continue dividend increasesJuly 2025 Snapshot & Long-Term Safe Investment Ideas - mfd.ru
Is InflaRx N.V. (IF0) stock among top earnings playsPortfolio Update Summary & Growth Oriented Trading Recommendations - mfd.ru
Inflarx N V (IFRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):